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Abstract
The pathological hallmark of amyotrophic lateral sclerosis (ALS) is the presence 
of cytoplasmic inclusions, containing C-terminal fragments of the protein TDP-
43. Here, we tested the hypothesis that highly sensitive mass spectrometry with 
parallel reaction monitoring (MS-PRM) can generate a high-resolution map of 
pathological TDP-43 peptide ratios to form the basis for quantitation of abnor-
mal C-terminal TDP-43 fragment enrichment. Human cortex and spinal cord, 
microscopically staged for the presence of p-TDP-43, p-tau, alpha-synuclein, 
and beta-amyloid pathology, were biochemically fractionated and analyzed by 
immunoblot and MS for the detection of full-length and truncated (disease-
specific) TDP-43 peptides. This informed the synthesis of heavy isotope-labeled 
peptides for absolute quantification of TDP-43 by MS-PRM across 16 ALS, 8 
Parkinson’s, 8 Alzheimer’s disease, and 8 aged control cases. We confirmed by 
immunoblot the previously described enrichment of pathological C-terminal 
fragments in ALS-TDP urea fractions. Subsequent MS analysis resolved spe-
cific TDP-43 N- and C-terminal peptides, including a novel N-terminal trun-
cation site-specific peptide. Absolute quantification of peptides by MS-PRM 
showed an increased C:N-terminal TDP-43 peptide ratio in ALS-TDP brain 
compared to normal and disease controls. A C:N-terminal ratio >1.5 discrimi-
nated ALS from controls with a sensitivity of 100% (CI 79.6–100) and specific-
ity of 100% (CI 68–100), and from Parkinson’s and Alzheimer’s disease with a 
sensitivity of 93% (CI 70–100) and specificity of 100% (CI 68–100). N-terminal 
truncation site-specific peptides were increased in ALS in line with C-terminal 
fragment enrichment, but were also found in a proportion of Alzheimer cases 
with normal C:N-terminal ratio but coexistent limbic TDP-43 neuropatholog-
ical changes. In conclusion this is a novel, sensitive, and specific method to 
quantify the enrichment of pathological TDP-43 fragments in human brain, 
which could form the basis for an antibody-free assay. Our methodology has the 
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1 |  INTRODUCTION
The presence of ubiquitylated cytoplasmic inclusions 
of the 43 kDa transactive region DNA-binding protein, 
TDP-43, is the neuropathological hallmark of the neu-
rodegenerative disorder amyotrophic lateral sclerosis 
(ALS) in 97% of all cases and 50% of cases of fronto-
temporal dementia (FTD) (1,2). TDP-43 histopathology 
also defines “limbic-predominant age-related TDP-
43 encephalopathy (LATE)” which may coexist with 
Alzheimer’s disease (AD) neuropathological change (3). 
However, the principal neuroanatomical distribution 
of microscopic TDP-43 pathology in LATE is distinct 
from that of classical ALS-TDP. The neuropathologi-
cal features of TDP-43 proteinopathy in ALS and FTD 
include nuclear to cytoplasmic mislocalization, post-
translational modifications such as ubiquitylation and 
phosphorylation, aggregation, and N-terminal trun-
cated C-terminal TDP-43 fragments (CTFs) (1,4). When 
extracting the insoluble protein fraction from post mor-
tem tissue with TDP-43 proteinopathy, a pathological 
signature can be detected by immunoblotting, which is 
characterized by a 45 kDa full-length protein band (the 
higher molecular mass smear representing posttransla-
tional modifications), and lower molecular weight bands 
(20–35 kDa), which have been identified as CTFs (1,5). 
Although TDP-43 neuropathology has been well defined 
using immunohistochemistry (6,7), biochemical detec-
tion of the pathological TDP-43 forms has so far been 
limited to semi-quantitative detection by immunoblot-
ting of the insoluble protein fractions from post mortem 
tissue and has not yet been reproduced in biofluids (8). 
Studies using antibodies against TDP-43 and its phos-
phorylated form to absolutely quantify pathological 
TDP-43 by ELISA in cerebrospinal fluid (CSF) or serum 
have provided inconsistent findings and antibodies have 
failed to detect phosphorylated TDP-43 or CTFs in lum-
bar CSF (9,10). Limitations are the significantly lower 
amounts of pathological TDP-43 present in a complex 
matrix such as CSF or serum, nonspecific binding of 
commercial antibodies to immunoglobulins, and the 
limited availability of antibodies that specifically detect 
pathological, brain-derived TDP-43, including discrim-
inating normal full-length TDP-43 from pathological 
truncated CTFs (11–13).
We aimed to develop an antibody-indepen-
dent method to biochemically detect CTFs by mass 
spectrometry to enable the absolute quantification of 
pathology. Detecting specific C- and N-terminal TDP-
43 peptides allowed us to measure the pathological accu-
mulation of C-terminal TDP-43 relative to its N-terminal 
end in urea fractions extracted from TDP-43 pathology 
positive ALS post mortem tissue. The detection of addi-
tional N-terminal truncation site-specific peptides was 
used to quantify the process of pathological cleavage of 
TDP-43 into N-terminal truncated CTFs. This method 
specifically discriminated ALS from other neurode-
generative diseases such as Parkinson’s disease (PD) 
and AD. Interestingly, by this method we were able to 
identify some cases of AD with coexistent LATE neuro-
pathological change (LATE-NC); however, further work 
is required to establish whether our method is suitable 
for the identification of disease-specific “TDP-43 strain 
signatures” associated with the spectrum of primary and 
secondary TDP-43 proteinopathies.
2 |  M ATERI A LS A N D M ETHODS
2.1 | Human samples
Primary motor cortex (BA4) or, if unavailable, dorso-
lateral prefrontal cortex (BA9/46) and spinal cords from 
individuals diagnosed with ALS, PD or AD, and from 
normal controls (CTL) were obtained from the Oxford 
Brain Bank. Donors had provided written informed 
consent for brain donation and the use of the material 
and clinical information for research purposes under 
Research Ethics Committee approval (REC 15/SC/0639, 
HTA license 12217).
2.2 | Clinical characteristics
For several ALS cases severity of physical symptoms 
was classified as per the revised ALS Functional Rating 
Scale (ALSFRS-R) with a maximum of 48 points. Here, 
lower values represent a more severe disease stage (14) 
and the progression rate was calculated as 48 minus the 
ALSFRS-R score at sampling divided by the disease 
duration from onset of symptoms and sampling (point/
month) (15). The region of onset was defined as where 
the first sign of disease was reported (spinal or bulbar) 
and the diagnostic certainty reported according to the 
potential to help clarify if specific pathological TDP-43 peptide signatures are 
associated with primary or secondary TDP-43 proteinopathies.
K E Y W O R D S
Alzheimer’s disease, amyotrophic lateral sclerosis, LATE, proteomic biomarker, TDP-43
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revised El Escorial Criteria (16). Post mortem delay was 
calculated in hours from time of death to fixation and 
the age at death was recorded. Genetic testing was only 
conducted in the presence of a clear family history.
2.3 | Immunohistochemistry for microscopic 
analysis of neurodegenerative proteinopathies
All cases were formally assessed for microscopically 
visible protein aggregates using standard criteria used 
in international brain banking (PMC3266529). In brief, 
formalin-fixed paraffin-embedded sections (six mi-
crons) were stained with the following primary anti-
bodies (source, dilution and antigen retrieval method in 
parentheses): phosphorylated TDP-43 (pTDP-43) that 
targets pS409/410 (Cosmobio, TIP-PTD-M01, 1:20,000, 
autoclave—citrate buffer); Anti-ß-Amyloid (4G8—
Biolegend, 1;24,000, formic acid); AT8 (Innogenetics, 
1:1500, none); and Purified Mouse Anti-alpha-Synuclein 
(BD Laboratories, 1:1000, formic acid). All were devel-
oped with the DAKO Envision Kit and 3,3-diaminoben-
zidine tetrahydrochloride (DAB) as chromogen. Sections 
were examined using an Olympus BX50 microscope with 
an attached Olympus digital camera (for photography).
2.4 | Extraction of soluble and insoluble 
protein fractions from tissue
Fractionation of tissue was performed as described by 
Neumann and colleagues (1), with the following modi-
fications. Frozen tissues from cortex and spinal cord of 
all groups of subjects were homogenized in 1:1 volume: 
tissue weight low-salt homogenization-solubilization 
(LS) buffer (10  mM Tris pH 8.0 (Invitrogen), 5  mM 
EDTA (Invitrogen), 1  mM dithiothreitol (Alfa Alsar) 
supplemented with protease and phosphatase inhibitors 
(Thermo Fisher), 0.2  mM Sodium orthovanadate, and 
0.3 Unit/µl benzonase (Merck)). Samples were homoge-
nized using steel beads in a TissueLyser system (Qiagen) 
and centrifuged at 21,000 g for 30 min at 4°C. The pellets 
were homogenized in Triton-X (TX) buffer (1% Triton 
X-100, 0.5  M NaCl in LS buffer). Protein amount was 
determined by BCA assay (Thermo Fisher) and all sam-
ples were equalized to 20 mg of total protein in a final 
volume of 3  ml Triton-X buffer. Tissue homogenates 
were centrifuged at 180,000 g for 30 min at 4°C in thin-
wall polypropylene tubes (Beckman Coulter) in swing-
ing buckets in an Optima MAX-XP ultracentrifuge 
(Beckman Coulter). Supernatants, corresponding to 
the soluble proteins, were saved as the Triton-X fraction 
(TX). Pellets were washed in TX buffer supplemented 
with 30% of sucrose (Merck). Pellets were subsequently 
resuspended in sarkosyl buffer (1% N-lauroyl-sarcosine 
(Merck), 0.5  M NaCl in LS buffer), briefly sonicated, 
and incubated at 37°C on a shaker (160 rpm) for 30 min 
followed by centrifugation at 180,000  g for 30  min at 
22°C. Supernatants were saved as the sarkosyl fraction 
(SF), while the pellets were resuspended in urea buffer 
(7 M urea (Merck), 2M Thiourea (Merck), 4% CHAPS 
(Thermo Fisher), and 30  mM Tris pH 8 (Invitrogen)) 
supplemented with protease and phosphatase inhibi-
tors (Thermo Scientific). Samples were sonicated and 
centrifuged for 30 min at 21,000 g at room temperature. 
The supernatant, corresponding to the insoluble frac-
tion, was saved as the urea-soluble fraction and frozen at 
−80°C prior to use. Four samples randomly chosen from 
each diagnostic group were fractionated together.
2.5 | Immunoblotting
The urea fractions were diluted in LDS sample buffer 
(Thermo Fisher) supplemented with reducing agents 
(Thermo Fisher) and boiled for 5 min. Proteins were sep-
arated on 10% NuPAGE pre-cast Bis-Tris gels (Thermo 
Fisher), transferred using an iBlot2 apparatus (Thermo 
Fisher). Membranes were Ponceau-stained, then blocked 
using protein free Blocking buffer (Thermo Fisher), 
and probed overnight at 4°C with a polyclonal TDP-43 
C-terminus antibody recognizing TDP-43 at epitopes 
from amino acid 260 onwards (Proteintech, 12892-1-AP) 
or phosphorylated TDP-43 at S409/410 (Proteintech, 
22309-1-AP) and 2 h at room temperature with second-
ary antibody rabbit HRP. Antibody signal was detected 
with ECL reagent (GE Healthcare) using a ChemiDoc 
MP Imaging System (Bio-Rad). For interpretation of 
the immunoblots the ratios of the intensities of the CTFs 
over full-length TDP-43 were compared.
2.6 | Silver staining
Total protein amounts were visualized by silver stain-
ing using a ProteoSilver Silver Stain kit (Merck) as per 
the manufacturer’s protocol and using solutions pro-
vided in the kit. Briefly, after electrophoresis, NuPAGE 
Bis-tris gels were fixed overnight at room temperature 
in fixing solution (10% acetic acid (Millipore) and 50% 
Ethanol (VWR) in MilliQ water). The gels were con-
secutively washed for 10 min in 30% Ethanol, MilliQ 
water, sensitizer solution, and silver solution. Staining 
was visualized by incubating with developer solution 
for 30–70  s, the reaction was stopped by addition of 
ProteoSilver Stop solution and washing with MilliQ 
water for 15 min.
2.7 | Sample preparation for mass 
spectrometry
Urea fractions were thawed on ice and used for diges-
tion. For in-gel digestion gel bands were excised with 
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a scalpel after electrophoresis and gel pieces rinsed in 
200 μl wash solution (50% methanol and 5% acetic acid 
in MilliQ water). Two-hundred microliters of acetoni-
trile was added to dehydrate the gel pieces prior to re-
duction with 5 mM DTT and alkylation with 20 mM 
IAA. After dehydration samples were first rehydrated 
in 200 μl of 100 mM ammonium bicarbonate and then, 
in 30 µl of 200 ng/µl chymotrypsin (Promega) in 50 mM 
ammonium bicarbonate and incubated overnight. 
Fifty microliters of 50  mM ammonium bicarbonate 
buffer was added to the samples, 50  µl of extraction 
buffer 1 (50% acetonitrile and 5% formic acid in MilliQ 
water) and 50  µl of extraction buffer 2 (85% acetoni-
trile and 5% formic acid in MilliQ water) were added 
and supernatant with eluted peptides collected. For in-
solution digestion samples were reduced with 5 mM of 
dithiothreitol (Alfa Alsar) followed by alkylation with 
20 mM IAA. Samples were subsequently precipitated 
by methanol–chloroform extraction. Pellets were fully 
resuspended by addition of 6  M urea buffer (Merck) 
and brief sonication. Samples were reduced to a final 
concentration of 1  M Urea by adding 50 mM TEAB 
buffer. The samples were incubated with 2 μg trypsin/
chymotrypsin (Promega) at 37°C/25°C on a shaker 
for 14–16 h. The reaction was stopped by addition of 
formic acid (Millipore). Samples were desalted using 
SOLA SPE columns (Thermo Fisher). All in-solution 
and in-gel digested samples were dried in a speed-vac 
(Thermo Scientific) and pellets were resuspended in 
2% acetonitrile with 0.1% formic acid diluted in MilliQ 
water.
2.8 | Discovery proteomics
Peptides from in-solution and in-gel digestion were 
analyzed by nano ultra-high-performance liquid chro-
matography (nano-UPLC) tandem mass spectrometry 
(MS/MS) using a Dionex Ultimate 3000 nano-UPLC, 
(Thermo Fisher) coupled to an Orbitrap Fusion Lumos 
Tribrid mass spectrometer (Thermo Fisher). Data were 
acquired in data-dependent mode with a resolution of 
120,000 full width half maximum at m/z 200 in the sur-
vey scan (375–1500  m/z) and with EASY-IC using the 
reagent ion source (202  m/z) for internal calibration. 
MS/MS spectra were acquired after precursor isola-
tion in the quadrupole with an isolation window of 1.2 
Th, dynamic precursor selection (top speed mode) with 
a 3-s fixed duty cycle time, and 60-s dynamic precur-
sor exclusion. Isolated precursor ions were fragmented 
by CID with a Normalized Collision Energy of 35%. 
Parallelization was enabled and MS/MS spectra were 
acquired in the linear ion trap for up to 250 ms with an 
ion target of 4000 in rapid scan mode. Raw MS data 
were analyzed using Progenesis QI for Proteomics v3.0 
(Nonlinear Dynamics). MS/MS spectra were searched 
against the UniProt Homo Sapiens Reference proteome 
(retrieved 15/11/2016) using PEAKS with precursor mass 
tolerance of 10  ppm and a fragment ion tolerance of 
0.5 Da. Carbamidomethylation of Cysteines was defined 
as a fixed modification, deamidation of Asparagine and 
Glutamine, and oxidation of Methionine as variable 
modifications. Peptides scoring ≥20 and FDR <1% were 
imported into Progenesis QIP.
2.9 | Truncation site-specific peptide 
identification
As previously described, in-gel digestion of low molec-
ular weight bands (20–28  kDa) of ALS urea fractions 
were used to identify the truncation site-specific TDP-
43 peptides (17). These peptides include one cleavage 
site independent of the enzyme used for digestion (giv-
ing a nonspecific digestion pattern), which suggests that 
cleavage has occurred endogenously prior to digestion. 
N-terminal nonspecific peptides have an N-terminal 
truncation site and cover an amino acid sequence toward 
the C-terminus of TDP-43, therefore, representing a spe-
cific truncation site of C-terminal low molecular weight 
fragments. The Truncation 2 peptide contained an ad-
ditional chymotryptic cleavage site after the position 5 
leucine residue, therefore, the endogenous peptide is only 
produced by (relatively less frequent) incomplete diges-
tion with chymotrypsin; a so-called “missed cleavage.” 
The yield of the missed cleavage containing peptide from 
digestion could be assumed to be substantial since the 
peptide had been observed in the discovery experiment, 
so the peptide was explored despite this issue. Also, there 
was a relatively lower yield of this peptide after diges-
tion in comparison to the other peptides, the mass spec-
trometer acquisition method was adapted to allow for 
this. The statistical analysis assumes that there was no 
significant variation in the site-specific missed cleavage 
rate of chymotrypsin (and, therefore, final peptide yield) 
between samples.
2.10 | Absolute quantification by parallel 
reaction monitoring
For the measurement of endogenous (light) TDP-43 pep-
tides by mass spectrometry with parallel reaction moni-
toring (MS-PRM), C- and N-terminal and truncation 
site-specific peptides detected from the discovery ex-
periments and a previously reported sequence (17) were 
used to generate heavy isotope-labeled (heavy) peptides. 
Heavy peptides were commercially synthesized using 
AQUA-grade (Thermo Fisher). One microliter of chymo-
trypsin-digested and desalted samples were injected into 
the mass spectrometer. A time schedule targeted MS/
MS method was used with peptide-specific parameters 
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as described in Table 2. Ten fmol of the heavy peptides 
listed was injected and, as technical quality check, pools 
of samples for each group were prepared and loaded every 
10th run to determine the reproducibility of the assay. 
Samples were randomized per diagnostic group and 
run in ascending order according to TDP-43 pathology 
(Ctrl, PD, AD, and ALS). MS data processing was con-
ducted by an independent investigator blinded for diag-
noses using the software packages Skyline and R. Briefly, 
Skyline was used to export ion chromatogram data for 
the light and heavy versions of each peptide in each anal-
ysis run as a text table that was then analyzed with an R 
script. The elution peaks of each light and heavy peptide 
pair were located in each sample. Pairs in each sample 
were filtered to remove those with insufficient signal for 
quantitation (minimum two monitorable fragment ion 
values measured over at least three collected spectra) or 
poor-quality data (Pearson correlation between light and 
heavy chromatogram data less than 0.5). Elution peak 
boundaries were assigned at the point where the heavy 
peptide signal dipped below 1% of its maximum intensity 
in that sample. Finally, a light-heavy ratio was calculated 
for each peptide by finding the gradient of a fitted simple 
linear model with no intercept (L = mH) to the light and 
heavy data points at each time point.
2.11 | Statistical analysis
For interpretation of the PRM results absolute abun-
dances of the light peptides (log10 ratio (light:heavy 
peptide)) were compared across diagnostic groups. The 
C:N-terminal peptide ratio was calculated by divid-
ing non-log absolute abundances of the light peptides. 
All significant differences were tested comparing ALS 
to all other diagnostic groups using one-way ANOVA 
with Dunnett’s multiple comparison test. p-values <0.05 
were considered as statistically significant. Standard 
measures of diagnostic test validity were performed on 
non-log abundances of the light peptides. Sensitivity, 
specificity, and predictive values accompanied by their 
confidence interval (CI) stated at the 95% level were cal-
culated for varying peptide cut-off levels. The optimal 
cut-off level for dichotomizing values was selected as 
the situation maximizing the Youden index (18). The re-
ceiver operating characteristics (ROC) curve is used for 
a graphical visualization of the impact of the variation in 
the cut-off values.
3 |  RESU LTS
3.1 | Post mortem characterisation
All clinical diagnoses were neuropathologically con-
firmed and the characteristic neuropathology of each 
diagnostic group used for the final MS-PRM analysis 
is shown in Figure  S1. TDP-43 neuropathology was 
qualitatively assessed using a phospho-TDP-43 anti-
body for the determination of typical inclusion pathol-
ogy. The tissue subjected to MS-PRM for the absolute 
quantification of peptides across diagnostic groups is 
presented in Table 1. The brain regions selected were 
motor cortex (region of the “hand knob”) or dorsolat-
eral prefrontal cortex. The AD group was significantly 
older than CTL, ALS, and PD. Post mortem time 
from death to fixation was the same between groups 
(p = 0.6). Clinical characteristics of patients are given 
in Table S1. ALS patients, who donated tissue for this 
study, reported no family history and were apparently 
sporadic ALS cases.
3.2 | Discovery of TDP-43-derived peptides in 
brain urea fractions
First, we used LC–MS/MS analysis to detect unique 
peptides for the absolute quantification of TDP-43 
(Figure 1A). In-solution digestion of two ALS and two 
CTL brain urea fractions revealed enzyme-specific 
TDP-43 peptides at the N-terminal and C-terminal end 
of TDP-43 (Table S2). Chymotrypsin digestion achieved 
the best peptide coverage of TDP-43 at its C-terminus 
to allow for the subsequent detection of CTFs. By 
in-gel digestion of low molecular weight bands (23–
28 kDa) of two ALS brain urea fractions we were able 
to detect truncation site-specific peptides that were 
semi-specific for the enzyme chymotrypsin (Table S3). 
This included a novel N-terminal truncation at amino 
acid 266 of TDP-43 representing a C-terminal TDP-43 
fragment detected at the size of 25 kDa (Truncation 2). 










CTL 8 (8/0) 8 (7/1/0) 65.9 (38–89) 4/4
PD 8 (5/3) 6 (6/0/0) 76.9 (69–80) 1/7
AD 8 (8/0) 8 (8/0/0) 84.3*** (78–93) 4/4
ALS 16 (13/3) 16 (12/3/1) 65.6 (49–86) 6/10
Abbreviations: f, female, m, male; n, number.
***Increased compared to all other groups (p < 0.001). 
TA B L E  1  Characteristics of the post 
mortem tissue cohort
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to the N-terminus of TDP-43 (aa175) was previously 
reported by Kametani et al., but not detected in our 
discovery analysis (17).
For absolute quantification of endogenous (light) 
peptides by MS-PRM the corresponding heavy iso-
tope-labeled analogs of a list of tryptic and chymo-
tryptic TDP-43 peptides were generated (Table S4) and 
tested for technical reliability. For the final MS-PRM 
analysis four chymotryptic peptides located at the 
N-and C-terminus of TDP-43 including truncation 1 
and 2 peptides were selected. The PRM properties of all 
four heavy peptides used for the final MS-PRM analysis 
are shown in Table 2.
3.3 | C-terminal TDP-43 fragments 
accumulate in the insoluble protein 
fraction of the ALS cortex
Insoluble protein fractions subjected to MS-PRM for the 
absolute quantification of TDP-43 and CTFs were also 
assessed by silver staining and immunoblotting for a 
F I G U R E  1  Urea fractionation of brain tissue for the enrichment of pathological TDP-43. (A) Schematic of sample processing and TDP-43 
peptide identification. Given are the peptides and their initial amino acid within the full-length TDP-43 protein. (B and C) Representative 
immunoblots with an anti-C-terminal TDP-43 antibody recognizing full-length (FL) TDP-43 at 43 kDa and smaller C-terminal fragments 
(CTFs) of the insoluble (urea) protein fractions from MS-PRM tissue cohort. (B) Cortex: Quantification of immunoreactive bands at 43 kDa, 
35 kDa and 25 kDa demonstrated that the CTF-35:FL TDP-43 ratio in ALS was only increased when compared to PD (p = 0.04). CTF-25:FL 
TDP-43 ratio in ALS was increased compared to CTL, PD, and AD (p = 0.03, p = 0.02, and p = 0.048). (C) Spinal cord: Immunoreactive 
bands showed unaltered CTF-35:FL and CTF-25:FL TDP-43 ratios in ALS compared to CTL, PD, and AD (p = 0.08, p = 0.17, and p = 0.053). 
Number of cases: 8 CTL, 8 PD, 8 AD, and 15 ALS. One-way ANOVA with Dunnett’s multiple comparison test
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semi-quantitative assessment of TDP-43 pathology char-
acteristics. Silver stains of the insoluble (urea) protein 
fractions from the same tissue cohort of 16 ALS, 8 PD, 8 
AD, and 8 CTL used for PRM were performed at equal 
volumes to verify the recovery of protein prior to diges-
tion and to confirm depletion of abundant proteins after 
sequential fractionation (Figure S2). The urea-enriched 
insoluble protein fractions were then immunoblotted 
with an anti-C-terminal TDP-43 antibody that recog-
nizes 20–35 kDa bands of pathologically cleaved TDP-43 
and the full-length form of TDP-43. This antibody was 
chosen to determine the ratio of the C-terminal lower 
TA B L E  2  Description of peptide origin and properties for PRM Validation
Origin (enzyme 
specificity) Heavy isotope-labeled peptides
Labeled 
residue






Relative ion collection 
target (time limit)
N-terminal (Specific) 5-I(R) 
VTEDENEPIEIPSEDDGTVL
+10 Da 43–88 (47.5) 0.54 ± 0.62 2+ 100% (50 ms)








266-SNRQLERSG(R)F +8 Da 20–30 (22.5) 0.017 ± 0.016 3+ 400% (100 ms)
The sequence of chymotrypsin specific or nonspecific (Truncation) heavy isotope-labeled peptides is given and the starting position within the TDP-43 amino acid 
sequence. () indicate heavy isotope-labeled amino acids (K Lysine, R Arginine, and G Glycine). Given are mean and standard deviation (SD)
Abbreviations: H, heavy peptide; L, light; ms, millisecond; RT, retention time.
F I G U R E  2  Quantification of C- and N-terminal TDP-43 peptides in motor and prefrontal cortex urea fractions by MS-PRM discriminates 
ALS from other neurodegenerative diseases. (A and B) Shown are absolute abundances of light peptides (log10 ratio (light:heavy peptide)) 
(A) The N-terminal peptide was decreased in ALS (n = 16) compared to AD (n = 8) (**p = 0.001), but not in ALS compared to CTL (n = 8) 
and PD (n = 8) (p = 0.13 and p = 0.051). (B) The C-terminal peptide was increased in ALS compared to PD (**p = 0.0045), but not in ALS 
compared to AD and CTL (p = 0.7, p = 0.29). (C) The calculated C:N-terminal peptide ratio was increased in ALS compared to AD, PD, and 
CTL (****p < 0.0001 respectively). One-way ANOVA with Dunnett’s multiple comparison test. (D) ROC curves of N-terminal and C-terminal 
peptide abundances and the calculated C:N-terminal peptide ratios for discrimination between ALS and CTL, PD or AD. For comparison, the 
AUCs are shown
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molecular weight bands to full-length TDP-43. In ac-
cordance with previous characterizations of the insolu-
ble protein fraction from ALS brains a strong reaction at 
25 kDa was detected in motor and prefrontal cortex urea 
fractions, suggesting that CTFs were present in addition 
to full-length TDP-43 at 43 kDa (1,5,6) (Figure 1B). We 
also observed a 35 kDa band and in some cases a higher 
molecular smear, likely to represent post-translationally 
modified TDP-43. When we calculated the ratio of CTF 
levels over full-length TDP-43 levels, an increase in the 
level of CTF-35 over the level of full-length TDP-43 was 
observed in ALS cortices compared to PD (p  =  0.04) 
and an increased level of CTF-25 in ALS compared to 
CTL, PD, and AD (p = 0.03, p = 0.02, and p = 0.048) in 
accordance with the enrichment of CTFs in ALS brain 
tissue (19). It is noteworthy that CTF-25 fragments were 
also detected in the urea fractions of AD cortices, but 
not significantly different from CTLs. In spinal cord 
urea fractions the smaller molecular weight bands at 
35 kDa and 25 kDa were less prominent and the CTF-
25 to full-length TDP-43 ratios unaltered between ALS 
and CTL, PD, and AD (p = 0.08, p = 0.17, and p = 0.053) 
(Figure 1C).
3.4 | Increased C:N-terminal TDP-43 peptide 
ratios in the insoluble protein fraction from 
motor and prefrontal cortex discriminate ALS 
from other neurodegenerative diseases
For the absolute quantification of CTFs targeted 
PRM using heavy isotope-labeled peptides was 
used. Quantification of four individual chymotryp-
tic peptides (log10 ratio (light peptide:heavy peptide), 
Figure  S3) showed that the N-terminal peptide was 
lower in the insoluble protein fraction from ALS cor-
tices compared to AD (p = 0.001) (Figure 2A). In con-
trast, the C-terminal peptide was increased in ALS 
compared to PD (p = 0.005) (Figure 2B), but unaltered 
between ALS and CTL or AD (p = 0.13 and p = 0.81). 
To investigate if peptide abundances reflect the path-
ological increase of CTFs in insoluble protein frac-
tions from ALS motor and prefrontal cortex tissue, we 
calculated the C:N-terminal peptide ratio. The C:N-
terminal peptide ratio was increased in ALS compared 
to all other diagnostic groups (p = 0.0001, respectively) 
(Figure 2C). This suggests that the C:N-terminal ratio 
is a highly specific marker of ALS representing the 
F I G U R E  3  Quantification of truncation site-specific TDP-43 peptides by MS-PRM identifies pathological TDP-43 processing in motor 
and prefrontal cortex urea fractions of ALS and AD. (A) and (C) Shown are absolute abundances of light peptides (log10 ratio (light:heavy 
peptide)) (A) The Truncation 1 peptide was increased in ALS (n = 16) compared to PD (n = 8) and CTL (n = 8) (****p < 0.0001, ***p = 0.0008), 
but not in ALS compared to AD (n = 8) (p = 0.94). Truncation 1 was increased in AD compared to PD and CTL (p = 0.0004 and 0.007). The 
Truncation 1: N-terminal peptide ratio was increased in ALS compared to AD, PD, and CTL (*p = 0.04, ****p < 0.0001 and p = 0.001). One-way 
ANOVA with Dunnett’s multiple comparison test. (B) ROC curves of the Truncation 1 abundance and the calculated Truncation 1: N-terminal 
peptide ratio for discrimination between ALS and CTL, PD or AD. For comparison, the AUCs are shown. (C) The Truncation 2 peptide was 
increased in ALS compared to PD and CTL (**p < 0.002, *p = 0.01), but decreased compared to AD (*p = 0.01). Truncation 2 was also increased 
in AD compared to PD and CTL (p < 0.0001 and p = 0.0001). The Truncation 2: N-terminal peptide ratio was increased in ALS compared to 
PD and CTL (**p = 0.004, **p = 0.007), but not AD (p = 0.79). One-way ANOVA with Dunnett’s multiple comparison test. (D) ROC curves of 
the Truncation 2 abundance and the calculated Truncation 2: N-terminal peptide ratio for discrimination between ALS and CTL, PD or AD. 
For comparison, the AUCs are shown
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enrichment of C-terminal TDP-43 protein fragments 
or a relative lack of N-terminal TDP-43 in the insolu-
ble protein fractions, or both.
To determine the potential of using C- and N-terminal 
peptide quantification as a diagnostic tool to discriminate 
ALS from other diseases, receiver operating characteris-
tic (ROC) analysis was used (Figure  2D). A N-terminal 
peptide abundance <0.3 yielded the optimal discrimina-
tion between ALS and AD, with 80% (CI 54.8–93.0) sen-
sitivity and 87.5% (CI 52.9–99.4) specificity. Applying this 
cut-off to the CTL group gave a diagnostic sensitivity of 
80% (CI 54.8–93.0) and specificity of 62.5% (CI 30.5–86.3), 
and for the PD group a sensitivity of 73% (CI 48.1–89.1) 
and specificity of 75% (CI 40.9–95.6). A C-terminal pep-
tide >0.3 yielded the optimal discrimination between ALS 
and PD, with a sensitivity of 86.7% (CI 62.1–97.6) and 100% 
(CI 67.6–100) specificity. Applying this cut-off to the CTL 
group gave a diagnostic sensitivity of 86.7% (CI 62.1–97.6) 
and specificity of 75% (CI 40.9–95.6), and to the AD group, 
a sensitivity of 86.7% (CI 62.1–97.6) and specificity of 50% 
(CI 21.5–78.5). A C:N-terminal peptide ratio >1.5 yielded 
the optimal discrimination between ALS and CTL, with a 
sensitivity of 100% (CI 79.6–100) and 100% specificity (CI 
67.6–100). Applying this cut-off to the PD and AD groups 
gave a diagnostic sensitivity of 93.3% (CI 70.2–99.7) and 
specificity of 100% (CI 67.6–100).
3.5 | Truncation peptides for the 
quantification of pathological cleavage of TDP-
43 in the insoluble protein fraction of ALS and 
AD motor and prefrontal cortices
To specifically quantify N-terminal truncation of TDP-43, 
to further proof the pathological truncation of TDP-43 in 
smaller CTFs, the truncation site-specific peptides were 
measured within the insoluble protein fraction from motor 
and prefrontal cortex tissue. Quantification of truncation 
site-specific peptide 1 (Truncation 1) showed an increase 
in ALS motor and prefrontal cortex urea fractions com-
pared to PD and CTL (p = 0.0008 and p < 0.0001, respec-
tively) (Figure 3A). Surprisingly, an increase of Truncation 
1 was also measured in AD cases compared to PD and 
CTL (p  =  0.0004 and 0.007). Only when calculating the 
Truncation 1: N-terminal peptide ratio an increase in ALS 
compared to AD was observed (p = 0.04) caused by the 
respective higher N-terminal peptide abundance in AD.
ROC analysis showed that a Truncation 1 peptide abun-
dance >0.005 yielded the optimal discrimination between 
ALS and PD, with a sensitivity of 100% (CI 67.56%–100.0%) 
and 100% specificity (CI 56.55%–100.0%) (Figure  3B). 
Applying this cut-off to the CTL group gave a sensitivity 
of 100% (CI 67.6–100) with 85.7% specificity (CI 48.7–99.3). 
The same cut-off value applied to the AD group showed 
a sensitivity of 100% (CI 67.6–100.0), but a low specificity 
of 20% (CI 1.0–62.5). The Truncation 1: N-terminal pep-
tide ratio >0.01 achieved a better discrimination between 
ALS and AD with a sensitivity of 100% (CI 67.6–100.0) and 
specificity of 40% (CI 7.1–76.9).
Quantification of the new truncation site-specific pep-
tide 2 (Truncation 2) showed a significant increase in ALS 
motor and prefrontal cortex urea fractions compared to PD 
and CTL (p = 0.001 and p = 0.01, respectively) (Figure 3C), 
but Truncation 2 was also increased in AD as compared to 
ALS (p = 0.01), PD, and CTL (p < 0.0001 and p = 0.0001). 
No significant difference between ALS and AD was ob-
served when calculating the Truncation 2: N-terminal 
peptide ratio (p = 0.79). According to this, ROC analysis 
demonstrated a Truncation 2 peptide abundance >0.004 
yielded the optimal discrimination between ALS and PD 
with a sensitivity of 100% (CI 70–100) and 100% specificity 
(CI 18–100) (Figure 3D). Applying this cut-off to the CTL 
group gave a sensitivity of 88.9% (CI 56.5–99.4) and speci-
ficity of 67% (CI 11.9–98.3). However, for ALS and AD only 
a cut-off value below 0.016 discriminated between both 
with a sensitivity of 77.8% (CI 45.3–96.1) and specificity of 
100% (CI 61.0–100). When the Truncation 2: N-terminal 
peptide ratio was calculated discrimination between AD 
and ALS decreased with an AUC of 0.61. This data clearly 
demonstrates that biochemically pathological cleavage of 
TDP-43 can be measured in both ALS and AD.
In summary, quantification of the TDP-43 peptide 
signature in motor and prefrontal cortex urea fractions 
showed that in ALS the C:N-terminal peptide ratio and 
truncation site-specific peptides were increased in the 
presence of TDP-43 neuropathology. In contrast, in AD 
motor cortex where TDP-43 neuropathology is micro-
scopically absent the C:N-terminal ratio was normal, 
but truncation site-specific peptides were similarly in-
creased (Figure 4A).
3.6 | MS-PRM quantification of TDP-43 
pathology correlates with phosphorylation of 
TDP-43 in brain
To investigate, if an increase of C:N-terminal peptide 
ratio and truncation peptides also represent pTDP-43 
pathology we immunoblotted motor cortex urea frac-
tions of ALS and AD cases with the highest MS-PRM 
values compared to PD and CTL cases. We observed the 
highest immunoreaction for pTDP-43 at 45 and 25 kDa 
in ALS followed by AD with LATE-NC, while pTDP-43 
was absent in PD and CTLs with low MS-PRM values 
(Figure 4B). As expected, normal full-length TDP-43 at 
45 kDa was present in all samples.
3.7 | Detection of biochemical 
cleavage of TDP-43 represents co-morbid TDP-
43 pathology in AD
Due to the biochemical evidence of pathological TDP-
43 truncation in AD motor cortex samples using highly 
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sensitive PRM, we sought to investigate if this finding 
represents the coexistence of LATE-NC in significant 
cases of AD. Therefore, we re-examined our cohort for 
microscopic evidence of pTDP-43 pathology. We found 
evidence of LATE-NC in six out of eight cases of AD, but 
not in PD, ALS, or controls confirming the sensitivity of 
F I G U R E  4  TDP-43 pathology and peptide quantification in ALS and AD brains. (A) In ALS motor cortices with positive pTDP-43 
pathology an increased C:N-terminal peptide ratio is present and increased abundance of Truncation 1 and 2 peptides confirms N-terminal 
cleavage of TDP-43. In AD motor cortices with absent pTDP-43 pathology the C:N-terminal peptide ratio is normal, but increased Truncation 
1 and 2 peptides are indicative of coexisting pathological processing of TDP-43. (B) Immunoblotting confirms pTDP-43 immunoreaction (left 
membrane) at 25 kDa and 45 kDa and a higher molecular smear (]) in ALS motor cortex (MI) with the highest MS-PRM values for C:N-
terminal ratio, Truncation 1 and 2 and at 45 kDa with a slight higher molecular smear in AD with LATE-NC in the hippocampus (HC) and 
Amygdala (Amy) (stage 2). PTDP-43 is absent in PD and CTL. After stripping FL TDP-43 at 43 kDa is present in all diagnostic groups (right 
membrane)
F I G U R E  5  Coexisting LATE neuropathological change in AD brain. Depicted is an AD case with the highest PRM values for Truncation 
1 and 2. pTDP-43 aggregates in (A) amygdala, (B) entorhinal cortex, and (C) hippocampal granule cells according to LATE-NC Stage 2. No 
pTDP-43 aggregates were visible in primary motor cortex (D) and hypoglossal nucleus (E, inset). Scale bar 20 µm
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our assay. The principal anatomical distribution of pTDP-
43 in LATE-NC was different from that typically found in 
ALS, mainly involving the amygdala, entorhinal cortex, 
and hippocampus, but not the motor cortex (Figure 5).
3.8 | C-terminal TDP-43 fragments are not 
increased in the urea fraction of spinal cord
To investigate the differences of TDP-43 pathology in af-
fected regions of ALS, we also investigated case-matched 
spinal cord samples. In contrast to data from the cortex, 
quantification of the N-terminal light:heavy peptide ratio 
in spinal cord urea samples showed an increase in ALS 
compared to CTL (p = 0.0001) (Figure 6A). The C-terminal 
peptide ratio was unaltered in ALS as compared to CTL 
(p = 0.3), PD, or AD (both p = 0.9) (Figure 6B). This sug-
gests the presence of N-terminal TDP-43 in spinal cord 
urea fractions compared to cortex urea fractions, in line 
with a previous immunohistochemistry analysis, which 
showed that cytoplasmic inclusions in the spinal cord 
stain with both a C-terminal TDP-43 and N-terminal 
TDP-43 antibody (6). When calculating the C:N-terminal 
peptide ratio to assess the proportion of C-terminal versus 
full-length TDP-43, a reverse pattern compared to cortex 
ALS urea fractions was observed, with an unaltered C:N-
terminal peptide ratio when compared to CTL (p = 0.1) 
(Figure  6C). Truncation site-specific peptide 1 was not 
detected in any of the samples regardless of the diagnostic 
groups while Truncation 2 was only detected in two CTL, 
one PD, and one AD sample.
4 |  DISCUSSION
Previous studies measuring TDP-43 in CSF and serum 
using antibody-based methods have revealed inconsist-
ent results due to the nonspecific binding of antibodies 
to full-length and pathologically altered TDP-43 (8,12). 
Post mortem validation of TDP-43 pathology currently 
relies on qualitative rather than absolute quantitative 
data (20). To overcome this problem, we have applied 
antibody-free proteomic discovery analysis for the de-
tection of TDP-43 and its potentially pathognomonic 
TDP-43 peptides in the insoluble protein fraction ex-
tracted from ALS brain tissue. A sophisticated targeted 
proteomic methodology was then developed for the ab-
solute quantification of those peptides across different 
diagnostic groups and identification of an ALS-specific 
peptide signature. This included peptides that were lo-
cated at the N-terminus, a peptide region that is also 
recognized by an antibody specifically detecting nuclear 
and, therefore, full-length TDP-43, and the C-terminus 
of TDP-43 found accumulated in pathological TDP-43 
aggregates in ALS brains (6,13). In addition, a novel 
truncation site-specific peptide with cleavage at amino 
acid 266, which has the potential to reflect N-terminal 
cleavage of CTFs, was identified at 25  kDa by in-gel 
digestion. The calculated molecular weight of the CTF 
generated by the new truncation is only 18 kDa, which 
either suggests homodimerization of different CTFs or 
post-translationally modification of peptides. The first 
is supported by the detection of other truncation site-
specific peptides within the same in-gel molecular weight 
range and also demonstrates low resolution of immuno-
blots. The pathological basis for the novel truncation 
site is unclear, as previously described reactions such 
as calpain- or caspase- cleavage to generate fragments 
of the size of 25 kDa and 35 kDa, or cleavage by other 
peptidases (PeptideCutter), do not occur on the relevant 
amino acid site (21,22). A peptidase independent mecha-
nism of asparagine cleavage and protein cross-linking 
has been described for long-lived proteins in aging such 
as Tau and Amyloid-ß (23).
Using combined peptide quantification by PRM 
showed that measuring an increased C:N-terminal 
F I G U R E  6  The C to N-terminal TDP-43 peptide ratio was not increased in ALS spinal cord urea fractions. (A and B) Shown are absolute 
abundances of light peptides (log10 ratio (light:heavy peptide)) (A) In contrast to motor and prefrontal cortex urea fractions the N-terminal 
peptide was increased in ALS compared to CTL (n = 8) (***p = 0.0001), but not in ALS (n = 16) compared to PD (n = 8) and AD (n = 8) (p = 0.14 
and p = 0.88). (B) The C-terminal peptide was unaltered in ALS compared to all other diagnostic groups (CTL p = 0.3, PD and AD p = 0.9). (C) 
The calculated C:N-terminal peptide ratio was unaltered in ALS compared to CTL (p = 0.1), PD or AD (both p = 0.9). One-way ANOVA with 
Dunnett’s multiple comparison test
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peptide ratio is a sensitive and highly specific marker 
for ALS TDP-43 pathology in brain. This is consistent 
with the accumulation of CTFs in urea fractions of 
ALS brain tissue as previously assessed by semi-quan-
titative measures (1). Our data, quantifying an increase 
of truncation site-specific peptides in ALS, also sup-
port N-terminal truncation as the disease-specific 
mechanism for C-terminal TDP-43 accumulation in 
the brain. Interestingly, this study also showed that the 
C:N-terminal peptide ratio was normal and truncation 
peptides were mostly absent in urea fractions from ALS 
spinal cords. This is in line with results from our immu-
noblots where no significant increase of the CTF-25 to 
full-length TDP-43 ratio was observed in spinal cords. 
This also confirmed previous immunohistochemical 
findings that cytoplasmic TDP-43 inclusions within the 
brain stain for C- but not N-terminal TDP-43, whereas 
ALS spinal cord TDP-43 inclusions are positive for both 
with a predominance of full-length over C-terminal 
TDP-43 (6,7). Whether this comes from alternative trun-
cation of TDP-43, as evidenced by the lack of detection 
of truncation site-specific peptides and unaltered CTF-
35 and CTF-25 to FL TDP-43 immunoblot ratios in spi-
nal cord, or as a result of different clearance mechanisms 
between cortical and spinal motor neurons, or neurons 
and glia, is unclear (24–27). This finding should prompt 
further investigation of differential pathological process-
ing of TDP-43 in relation to different neuroanatomical 
regions across clinical subtypes of TDP-43 proteinopa-
thy defined by regional heterogeneity (19,28,29).
Our work also revealed a pathological TDP-43 signa-
ture in some cases with the primary neuropathological 
diagnosis of severe end-stage AD. These cases had in-
creased truncation peptides, but a normal C:N-terminal 
peptide ratio in motor cortex urea fractions. We were able 
to confirm that those AD cases harbored the recently 
described LATE-NC in the amygdala and hippocampus. 
Interestingly, the pathological TDP-43 peptide signature 
was detected in motor cortex, brain areas that are not 
known to be affected in immunohistochemically deter-
mined stages of LATE-NC. We speculate that this might 
indicate that mass-spectrometric detection of trunca-
tion of TDP-43 may represent a biochemical signal of 
emerging TDP-43 proteinopathy before visible, compact 
microscopic aggregates are found. However, a definitive 
study on this subject will require more extensive multire-
gional sampling for MS-PRM of those brain regions af-
fected in LATE-NC including the middle frontal gyrus. 
MS-PRM and combined unbiased quantitative neuro-
pathology across ALS, FTD, and LATE-NC will be re-
quired to comment on the diverse forms of primary and 
secondary human brain TDP-43 proteinopathies (30,31).
A limitation of this study is that the detection of the 
disease-specific peptide signature of TDP-43 by MS-
PRM was in insoluble protein fractions of tissue, where 
pathological TDP-43 accumulates. Furthermore, the 
sensitivity to identify the pathological TDP-43 peptide 
signature in whole brain homogenate, where also soluble 
TDP-43 is present, still needs to be determined.
In conclusion, we show that the detection of a specific 
peptide signature enables the absolute quantification of 
TDP-43 pathology in the insoluble protein fraction of 
brain tissue by MS-PRM. The measurement of patholog-
ical CTF accumulation in post mortem ALS brain tissue 
allows accurate discrimination from other neurodegen-
erative diseases. If such a signature can be detected by 
MS-PRM in accessible biofluids such as serum and CSF 
or extracellular vesicles isolated from CSF, this approach 
may be ideally suited for the development of a biofluid 
assay for ALS-TDP and, potentially, other TDP-43 
proteinopathies.
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Supplementary Material
FIGURE S1 Neuropathology of the study cohort. (A) 
ALS-TDP with granular-, skein- and neuritic pTDP-43 
aggregates in the motor cortex (layer three) and nucleus 
hypoglossus (inset). (B) PD with alpha-synuclein-posi-
tive Lewy bodies, granular deposits and Lewy neurites 
inthe substantia nigra (inset: pigmented dopaminergic 
neuron with Lewy body H&E). (C and D) classical AD 
with a neuritic beta-amyloid-positive plaque (C) and 
neurofibrillary tangles in the granule cells of the hip-
pocampus (D) (serial sections). Scale bar 20 μm
FIGURE S2 Silver stains of insoluble and soluble pro-
tein fractions. Representative silver stains demonstrate 
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the total protein amount of (A) 0.5 μl of the soluble (TX) 
protein fractions. (B) 1 μl of the insoluble (urea) protein 
fractions extracted from cortex and spinal cord post mor-
tem tissue of CTL, ALS, PD and AD patients. Depletion 
of abundant proteins is demonstrated in urea fractions
FIGURE S3 Skyline export of light and heavy peptides 
for PRM analysis. Representative Skyline exports shown 
with Savitzky-Golay (also known as LOESS) retrieved 
from a pooled ALS cortex urea fraction sample. The 
top row represents light peptides and the bottom row 
heavy isotope-labelled peptides, where different co-
loured graphs represent fragment ions. (A) N-terminal 
chymotryptic light and heavy peptide. (B) C-terminal 
chymotryptic light and heavy peptide. (C) Truncation 1 
chymotryptic light and heavy peptide. (D) Truncation 2 
chymotryptic light and heavy peptide
TABLE S1 Detailed characteristics of post mortem tissue
TABLE S2 Detection of TDP-43 peptides from in-solu-
tion trypsin digestions of cortex urea fractions from ALS 
and CTL cases
TABLE S3 Detection of semi-specific truncation 
site-specific TDP-43 peptides from chymotrypsin in-gel 
digestion of cortex urea fractions
TABLE S4 List of TDP-43 peptides for heavy isotope- 
labelled peptide production
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